MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))
Phase 2Small molecule
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) is one of 37 small molecule programs targeting Autism Spectrum Disorder. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
36
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
160 competitors in Autism Spectrum Disorder
#DrugCompanyPhaseTrials
1Vraylar
AbbViePhase 3
Elavil
AstraZenecaPhase 3
Bumex
VValidus Pharmaceuticals
Phase 3
Rexulti
OtsukaPhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 3
Hetlioz
VVanda Pharmaceuticals
Phase 3
Glucophage
EMD SeronoPhase 3
Lithobid
SSolvay Pharmaceuticals
Phase 3
Circadin
NNeurim Pharmaceuticals Ltd.
Phase 3
Karx-EC
Bristol-Myers SquibbPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- DDefinium Therapeutics US, Inc.